Myelofibrosis causes: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}{{AE}}{{MJK}} | {{CMG}}{{AE}}{{MJK}} | ||
==Overview== | ==Overview== | ||
Myelofibrosis is caused by a mutation in ''[[JAK2]]'', ''[[Calreticulin|CALR]]'', and ''[[Myeloproliferative leukemia virus oncogene|MPL]]'' genes.<ref name="TefferiLasho2014">{{cite journal|last1=Tefferi|first1=A|last2=Lasho|first2=T L|last3=Finke|first3=C M|last4=Knudson|first4=R A|last5=Ketterling|first5=R|last6=Hanson|first6=C H|last7=Maffioli|first7=M|last8=Caramazza|first8=D|last9=Passamonti|first9=F|last10=Pardanani|first10=A|title=CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons|journal=Leukemia|volume=28|issue=7|year=2014|pages=1472–1477|issn=0887-6924|doi=10.1038/leu.2014.3}}</ref> | Myelofibrosis is caused by a mutation in ''[[JAK2]]'', ''[[Calreticulin|CALR]]'', and ''[[Myeloproliferative leukemia virus oncogene|MPL]]'' genes.<ref name="TefferiLasho2014">{{cite journal|last1=Tefferi|first1=A|last2=Lasho|first2=T L|last3=Finke|first3=C M|last4=Knudson|first4=R A|last5=Ketterling|first5=R|last6=Hanson|first6=C H|last7=Maffioli|first7=M|last8=Caramazza|first8=D|last9=Passamonti|first9=F|last10=Pardanani|first10=A|title=CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons|journal=Leukemia|volume=28|issue=7|year=2014|pages=1472–1477|issn=0887-6924|doi=10.1038/leu.2014.3}}</ref><ref name="pmid15781101">{{cite journal |author=Baxter EJ, Scott LM, Campbell PJ, ''et al'' |title=Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders |journal=Lancet |volume=365 |issue=9464 |pages=1054–61 |year=2005 |pmid=15781101 |doi=10.1016/S0140-6736(05)71142-9 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(05)71142-9}}</ref><ref name="pmid16834459">{{cite journal |author=Pikman Y, Lee BH, Mercher T, ''et al'' |title=MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia |journal=PLoS Med. |volume=3 |issue=7 |pages=e270 |year=2006 |month=July |pmid=16834459 |pmc=1502153 |doi=10.1371/journal.pmed.0030270 |url=http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030270}}</ref> | ||
==Causes== | ==Causes== | ||
Myelofibrosis is caused by a mutation in the following genes: | |||
<ref name="TefferiLasho2014">{{cite journal|last1=Tefferi|first1=A|last2=Lasho|first2=T L|last3=Finke|first3=C M|last4=Knudson|first4=R A|last5=Ketterling|first5=R|last6=Hanson|first6=C H|last7=Maffioli|first7=M|last8=Caramazza|first8=D|last9=Passamonti|first9=F|last10=Pardanani|first10=A|title=CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons|journal=Leukemia|volume=28|issue=7|year=2014|pages=1472–1477|issn=0887-6924|doi=10.1038/leu.2014.3}}</ref><ref name="pmid15781101">{{cite journal |author=Baxter EJ, Scott LM, Campbell PJ, ''et al'' |title=Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders |journal=Lancet |volume=365 |issue=9464 |pages=1054–61 |year=2005 |pmid=15781101 |doi=10.1016/S0140-6736(05)71142-9 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(05)71142-9}}</ref><ref name="pmid16834459">{{cite journal |author=Pikman Y, Lee BH, Mercher T, ''et al'' |title=MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia |journal=PLoS Med. |volume=3 |issue=7 |pages=e270 |year=2006 |month=July |pmid=16834459 |pmc=1502153 |doi=10.1371/journal.pmed.0030270 |url=http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030270}}</ref> | |||
*''[[JAK2]]'' | |||
*''[[Calreticulin|CALR]]'' | |||
*''[[Myeloproliferative leukemia virus oncogene|MPL]]'' | |||
*Bone marrow is the soft, fatty tissue inside bones, responsible for hematopoiesis. Stem cells are immature cells in the bone marrow that give rise to all of your blood cells. Blood is made of: | *Bone marrow is the soft, fatty tissue inside bones, responsible for hematopoiesis. Stem cells are immature cells in the bone marrow that give rise to all of your blood cells. Blood is made of: | ||
:*Red blood cells (which carry oxygen to tissues) | :*Red blood cells (which carry oxygen to tissues) | ||
Revision as of 16:12, 12 November 2015
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis causes On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis causes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Myelofibrosis is caused by a mutation in JAK2, CALR, and MPL genes.[1][2][3]
Causes
Myelofibrosis is caused by a mutation in the following genes: [1][2][3]
- Bone marrow is the soft, fatty tissue inside bones, responsible for hematopoiesis. Stem cells are immature cells in the bone marrow that give rise to all of your blood cells. Blood is made of:
- Red blood cells (which carry oxygen to tissues)
- White blood cells (which fight infections)
- Platelets (which help blood clot)
- Scarring of the bone marrow means the marrow is not able to make enough blood cells. Anemia, bleeding tendency, and a higher risk of infections may occur.
- As a result, the liver and spleen make some of these blood cells. This causes these organs to swell, which is called extramedullary hematopoiesis.
- The cause of myelofibrosis is unknown. There are no known risk factors. The disorder usually develops slowly in people over age 50.
- Diseases such as leukemia and lymphoma may also cause bone marrow scarring. This is called secondary myelofibrosis.
References
- ↑ 1.0 1.1 Tefferi, A; Lasho, T L; Finke, C M; Knudson, R A; Ketterling, R; Hanson, C H; Maffioli, M; Caramazza, D; Passamonti, F; Pardanani, A (2014). "CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons". Leukemia. 28 (7): 1472–1477. doi:10.1038/leu.2014.3. ISSN 0887-6924.
- ↑ 2.0 2.1 Baxter EJ, Scott LM, Campbell PJ; et al. (2005). "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders". Lancet. 365 (9464): 1054–61. doi:10.1016/S0140-6736(05)71142-9. PMID 15781101.
- ↑ 3.0 3.1 Pikman Y, Lee BH, Mercher T; et al. (2006). "MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia". PLoS Med. 3 (7): e270. doi:10.1371/journal.pmed.0030270. PMC 1502153. PMID 16834459. Unknown parameter
|month=ignored (help)